Functional analysis of an LGN-based visual prosthesis
基于 LGN 的视觉假体的功能分析
基本信息
- 批准号:10582766
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:Accidental FallsAgeAge related macular degenerationAgingAnatomyAnimalsAreaBilateralBlindnessBrainCellsChronicClinicalClinical ResearchDevelopmentDevice DesignsDevicesDiabetes MellitusDiabetic RetinopathyDiseaseEffectivenessElectric StimulationElectrodesEvaluationEyeEye InjuriesFoundationsFutureGeneral PopulationGeneticGlaucomaImplantIn VitroIndividualInvestigationLateral Geniculate BodyLearningMapsMental DepressionMusNeuronsObesityOcular ProsthesisOutcomePathway interactionsPatientsPatternPerformancePharmacologic SubstancePhysiologyPopulationPositioning AttributeProsthesisRetinaSchemeSecondary toShapesSignal TransductionSiteSoldierStructureSurfaceTechnologyTestingThalamic structureTimeTissuesTraumaUnemploymentVeteransVisionVisualVisual Cortexarea striatablindcell typecombatimplantable deviceimplantationmemberneuralneurotransmissionoptogeneticspreclinical studyresponseretina implantationsight restorationstem cellstransmission process
项目摘要
We are developing a visual prosthesis that can restore vision to the blind. Finding a treatment for blindness is
significant as it is projected to impact 1 in 28 individuals over the age of 45 by the year 2030 (~3.5% of the
population), including over 100,000 Veterans. Further, blindness is associated with increased levels of
depression, obesity, diabetes, and accidental falls, and estimates suggest two-thirds of the blind are
unemployed. Potential treatments are under development, including pharmaceutical, genetic, stem cell,
optogenetic and prosthetic approaches, but almost all target the retina and thus offer little hope to a large
portion of the blind population. This includes battlefield soldiers, returning from combat with bilateral traumatic
eye injury, and other members of the general population with similar afflictions. It also includes those with
glaucoma, age-related macular degeneration, and diabetic retinopathy, the 3 most common cause of blindness
in aging Veterans (and the general population). The lateral geniculate nucleus (LGN) of the thalamus is an
attractive site for implantation of a prosthesis as it is beyond the disease/trauma associated with most causes
of blindness and thus a working device would offer a treatment to large portions of the blind population. In
addition, the LGN is more spatially expansive than the retina and thus allows for a larger number of stimulation
sites and higher acuity. At the same time, the neural signaling patterns used by LGN neurons are much less
abstract than those of the visual cortex, thereby allowing for more straightforward encoding schemes (than
those required by cortical prostheses). While it has been challenging to develop a high-count, multi-channel
device that can safely be implanted into a deep brain structure, our colleagues have recently developed such a
device and much effort is underway to advance this technology. However, little is known about how to
effectively stimulate the LGN with a prosthesis and this lack of understanding will impede progress towards a
clinical device. Here, we propose 4 Aims focused on learning how to effectively drive LGN neurons with a
prosthesis. Our initial testing shows that stimulation from of the LGN can indeed drive downstream visual
circuits and further, that primary visual cortex (V1) is activated as well (secondary to the activation of the LGN).
Thus, our Aims will focus on determining how to most effectively activate the LGN and we will explore whether
the same conditions that maximize LGN activation also produce robust activation of visual cortex. As part of
this investigation, we will also explore whether individual cell types in LGN have different sensitivities to electric
stimulation as is the case in many other regions of the CNS. This will be quite useful as the different layers of
LGN are comprised of different cell types and understanding how to optimally activate each may lead to better
outcomes. Finally, we will evaluate the stability of performance for implanted devices for chronic implantation.
We believe that the comprehensive evaluation proposed here will provide a foundation from which to
systematically advance future pre-clinical and clinical studies.
我们正在研制一种能使盲人恢复视力的视觉假体。找到治疗失明的方法
重要的是,预计到2030年,每28名45岁以上的人中就有1人受到影响(约占人口的3.5%)。
其中包括10万多名退伍军人。此外,失明与增加的
抑郁症、肥胖症、糖尿病和意外福尔斯,估计三分之二的盲人是
失业潜在的治疗方法正在开发中,包括药物,遗传,干细胞,
光遗传学和假体方法,但几乎所有的目标是视网膜,因此提供了一个大的希望不大,
部分盲人。这包括战场士兵,从战斗中返回,
眼睛受伤,以及其他患有类似疾病的普通人群。它还包括那些与
青光眼、年龄相关性黄斑变性和糖尿病视网膜病变,这三种最常见的致盲原因
老年退伍军人(和一般人群)。丘脑的外侧膝状体核(LGN)是一个神经元,
假体植入的有吸引力的部位,因为它超出了与大多数原因相关的疾病/创伤
因此,一种有效的装置将为大部分盲人提供治疗。在
此外,LGN比视网膜在空间上更扩张,因此允许更大数量的刺激
网站和更高的敏锐度。同时,LGN神经元使用的神经信号模式要少得多
比视觉皮层更抽象,从而允许更直接的编码方案(比
皮质假体所需的那些)。虽然开发高计数、多通道的
一种可以安全植入大脑深层结构的设备,我们的同事最近开发了这样一种设备,
设备和许多努力正在进行中,以推进这项技术。然而,人们对如何
有效地刺激LGN与假肢,这种缺乏了解将阻碍进展,
临床器械。在这里,我们提出了4个目标,重点是学习如何有效地驱动LGN神经元,
假肢我们的初步测试表明,来自LGN的刺激确实可以驱动下游视觉,
此外,初级视觉皮层(V1)也被激活(继发于LGN的激活)。
因此,我们的目标将集中在确定如何最有效地激活LGN,我们将探讨是否
使LGN激活最大化的相同条件也产生视觉皮层的强激活。的一部分
在这项研究中,我们还将探讨LGN中的单个细胞类型是否对电刺激具有不同的敏感性。
刺激的情况下,在许多其他地区的中枢神经系统。这将是非常有用的,因为不同层的
LGN由不同的细胞类型组成,了解如何最佳地激活每种细胞类型可能会导致更好的
结果。最后,我们将评价长期植入器械的性能稳定性。
我们认为,这里提议的全面评估将提供一个基础,
系统地推进未来临床前和临床研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shelley Fried其他文献
Shelley Fried的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shelley Fried', 18)}}的其他基金
Investigating the Response of CNS Neurons to Electric and Magnetic Stimulation
研究中枢神经系统神经元对电和磁刺激的反应
- 批准号:
10673590 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Optimization of micro-coil arrays for precise stimulation of visual cortex
优化微线圈阵列以精确刺激视觉皮层
- 批准号:
10362524 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Informing the Sub-Retinal Approach to Stimualation of the Retina.
告知视网膜下刺激视网膜的方法。
- 批准号:
8083729 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Informing the Sub-Retinal Approach to Stimualation of the Retina.
告知视网膜下刺激视网膜的方法。
- 批准号:
8240901 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Informing the Sub-Retinal Approach to Stimualation of the Retina.
告知视网膜下刺激视网膜的方法。
- 批准号:
8926963 - 财政年份:2011
- 资助金额:
-- - 项目类别:
The mechanism by which electric stimulation activates retinal neurons
电刺激激活视网膜神经元的机制
- 批准号:
8599463 - 财政年份:2010
- 资助金额:
-- - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-SCREEN:基于人工智能的现实基础设施,用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展,提供可及的共享护理
- 批准号:
10102692 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
抑制新生血管性年龄相关性黄斑变性的新生血管形成和视网膜下纤维化
- 批准号:
10639785 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Inhibition of melanogenesis in retinal pigment epithelium, a contributing factor in age-related macular degeneration
抑制视网膜色素上皮中的黑色素生成,这是年龄相关性黄斑变性的一个促成因素
- 批准号:
23K09052 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
年龄相关性黄斑变性的新型抗炎治疗方法的评价
- 批准号:
10642988 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
- 批准号:
10635325 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Cellular and molecular mechanisms of AIM2 and NLRP3 inflammasome activation in age-related macular degeneration
年龄相关性黄斑变性中 AIM2 和 NLRP3 炎症小体激活的细胞和分子机制
- 批准号:
10584110 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Elucidation of roles of mast cells and macrophages in the pathogenesis of age-related macular degeneration
阐明肥大细胞和巨噬细胞在年龄相关性黄斑变性发病机制中的作用
- 批准号:
22H03243 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
AMD Mitochondria Modulate Expression of microRNA 135b-5p and 148a-3p in RPE Cybrids: Implications for Age-related Macular Degeneration
AMD 线粒体调节 RPE Cybrids 中 microRNA 135b-5p 和 148a-3p 的表达:对年龄相关性黄斑变性的影响
- 批准号:
10433610 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Targeting the inflammatory response in age-related macular degeneration
针对年龄相关性黄斑变性的炎症反应
- 批准号:
10504138 - 财政年份:2022
- 资助金额:
-- - 项目类别: